WAIKOLOA, Hawaii — At Hawaiian Eye/Retina 2016, Jay S. Duker, MD, discusses his presentations on OCT angiography and his belief that the three-dimensional angiograms will be particularly useful in choroidal neovascularization and neovascularization of the retina.
WAIKOLOA, Hawaii — At Hawaiian Eye, Audrey R. Talley-Rostov, MD, discusses the importance of taking care of underlying corneal pathology before cataract surgery to achieve the best visual outcomes.
WAIKOLOA, Hawaii — Robert D. Fechtner, MD, professor of ophthalmology at Rutgers University, New Jersey, was named Speaker of the Day for the Comprehensive Ophthalmology Program for his presentation that challenged the value of the ‘one eye’ trial. Elias Reichel , MD, of New England Eye Center, Boston, was named Speaker of the Day for Retina 2016 for his talk that explored the role of laser in the treatment of retinal vascular conditions.
WAIKOLOA, Hawaii — Henry Baylis, MD, was the recipient the 2016 Philip M. Corboy, MD, Memorial Award for Distinguished Service to Ophthalmology here during the Hawaiian Eye Foundation Symposium at Hawaiian Eye. The award was presented by Jeffrey Rutgard, MD, the 2015 Thornton Humanitarian Award winner for Exceptional Worldwide Ophthalmic Care.
WAIKOLOA, Hawaii — Because it is as effective as primary glaucoma medications, and it is less expensive and safer than medications with no patient compliance issues, selective laser trabeculoplasty should be considered as a first line therapy for some glaucoma patients, according to a speaker here.“In the majority of patients in the trabecular meshwork for Schlemm’s canal, there is a problem with outflow. All of the current drugs that we are using really don’t address that particular problem,” L. Jay Katz, MD, said at Hawaiian Eye. “There has been a fair amount of work done with laser trabeculoplasty showing that it seems to work in lowering IOP and improving trabecular or conventional outflow in the eye.”
WAIKOLOA, Hawaii — The long-held belief that the “one eye” trial of medication is an efficient solution for assessing treatment efficacy for lowering IOP is not true, and the practice should be abandoned, according to a speaker here. “The one eye trial does not work in any way shape or form that is efficient enough for us,” Robert D. Fechtner, MD, told colleagues at Hawaiian Eye. “The one eye trial has been taught throughout my career and has been a standard and advocated. The theory behind the one eye trial is you measure the pressure in both eyes, you treat one eye for 4 weeks or so, and then you measure the pressure in both eyes. You look at the change in the treated eye against the change in the untreated eye, and that’s your therapeutic effect.”